Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
Identifieur interne : 000064 ( Main/Exploration ); précédent : 000063; suivant : 000065Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
Auteurs : Maryse Lapeyre-Mestre [France] ; Alexandra Boucher [France] ; Amélie Daveluy [France] ; Valérie Gibaja [France] ; Emilie Jouanjus [France] ; Michel Mallaret [France] ; Helene Peyrière [France] ; Joëlle Micallef [France]Source :
- Therapie [ 1958-5578 ]
Descripteurs français
- KwdFr :
- France (épidémiologie), Humains (MeSH), Infections à coronavirus (épidémiologie), Mauvais usage des médicaments prescrits (épidémiologie), Médecins généralistes (organisation et administration), Pandémies (MeSH), Personnel de santé (organisation et administration), Pneumopathie virale (épidémiologie), Quarantaine (MeSH), Services des pharmacies communautaires (organisation et administration), Troubles liés à une substance (complications), Troubles liés à une substance (épidémiologie).
- MESH :
- organisation et administration : Médecins généralistes, Personnel de santé, Services des pharmacies communautaires.
- épidémiologie : France, Infections à coronavirus, Mauvais usage des médicaments prescrits, Pneumopathie virale, Troubles liés à une substance.
- Humains, Pandémies, Quarantaine.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Community Pharmacy Services (organization & administration), Coronavirus Infections (epidemiology), Drug Overdose (epidemiology), France (epidemiology), General Practitioners (organization & administration), Health Personnel (organization & administration), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Quarantine (MeSH), Substance-Related Disorders (complications), Substance-Related Disorders (epidemiology).
- MESH :
- geographic , epidemiology : France.
- complications : Substance-Related Disorders.
- epidemiology : Coronavirus Infections, Drug Overdose, Pneumonia, Viral, Substance-Related Disorders.
- organization & administration : Community Pharmacy Services, General Practitioners, Health Personnel.
- Humans, Pandemics, Quarantine.
Abstract
Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role: among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (https://sfpt-fr.org/covid19). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances.
DOI: 10.1016/j.therap.2020.06.006
PubMed: 32660776
PubMed Central: PMC7309935
Affiliations:
- France
- Aquitaine, Auvergne-Rhône-Alpes, Grand Est, Languedoc-Roussillon, Lorraine (région), Midi-Pyrénées, Nouvelle-Aquitaine, Occitanie (région administrative), Provence-Alpes-Côte d'Azur, Rhône-Alpes
- Bordeaux, Grenoble, Lyon, Marseille, Montpellier, Nancy, Toulouse
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Addictovigilance contribution during COVID-19 epidemic and lockdown in France.</title><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Toulouse, 31000 Toulouse, France. Electronic address: maryse.lapeyre-mestre@univ-tlse3.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Boucher, Alexandra" sort="Boucher, Alexandra" uniqKey="Boucher A" first="Alexandra" last="Boucher">Alexandra Boucher</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Lyon, 69424 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Lyon, 69424 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Daveluy, Amelie" sort="Daveluy, Amelie" uniqKey="Daveluy A" first="Amélie" last="Daveluy">Amélie Daveluy</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Bordeaux, 33076 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Bordeaux, 33076 Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Gibaja, Valerie" sort="Gibaja, Valerie" uniqKey="Gibaja V" first="Valérie" last="Gibaja">Valérie Gibaja</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Nancy, 54035 Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Nancy, 54035 Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Jouanjus, Emilie" sort="Jouanjus, Emilie" uniqKey="Jouanjus E" first="Emilie" last="Jouanjus">Emilie Jouanjus</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Toulouse, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Mallaret, Michel" sort="Mallaret, Michel" uniqKey="Mallaret M" first="Michel" last="Mallaret">Michel Mallaret</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Grenoble, 38043 Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Grenoble, 38043 Grenoble</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Peyriere, Helene" sort="Peyriere, Helene" uniqKey="Peyriere H" first="Helene" last="Peyrière">Helene Peyrière</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Montpellier, 34295 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Montpellier, 34295 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Marseille, 13385 Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Marseille, 13385 Marseille</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020 Jul - Aug</date><idno type="RBID">pubmed:32660776</idno><idno type="pmid">32660776</idno><idno type="doi">10.1016/j.therap.2020.06.006</idno><idno type="pmc">PMC7309935</idno><idno type="wicri:Area/Main/Corpus">000992</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000992</idno><idno type="wicri:Area/Main/Curation">000992</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000992</idno><idno type="wicri:Area/Main/Exploration">000992</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Addictovigilance contribution during COVID-19 epidemic and lockdown in France.</title><author><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Toulouse, 31000 Toulouse, France. Electronic address: maryse.lapeyre-mestre@univ-tlse3.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Boucher, Alexandra" sort="Boucher, Alexandra" uniqKey="Boucher A" first="Alexandra" last="Boucher">Alexandra Boucher</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Lyon, 69424 Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Lyon, 69424 Lyon</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Daveluy, Amelie" sort="Daveluy, Amelie" uniqKey="Daveluy A" first="Amélie" last="Daveluy">Amélie Daveluy</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Bordeaux, 33076 Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Bordeaux, 33076 Bordeaux</wicri:regionArea><placeName><region type="region" nuts="2">Nouvelle-Aquitaine</region><region type="old region" nuts="2">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Gibaja, Valerie" sort="Gibaja, Valerie" uniqKey="Gibaja V" first="Valérie" last="Gibaja">Valérie Gibaja</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Nancy, 54035 Nancy, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Nancy, 54035 Nancy</wicri:regionArea><placeName><region type="region" nuts="2">Grand Est</region><region type="old region" nuts="2">Lorraine (région)</region><settlement type="city">Nancy</settlement></placeName></affiliation></author><author><name sortKey="Jouanjus, Emilie" sort="Jouanjus, Emilie" uniqKey="Jouanjus E" first="Emilie" last="Jouanjus">Emilie Jouanjus</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Toulouse, 31000 Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Toulouse, 31000 Toulouse</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Midi-Pyrénées</region><settlement type="city">Toulouse</settlement></placeName></affiliation></author><author><name sortKey="Mallaret, Michel" sort="Mallaret, Michel" uniqKey="Mallaret M" first="Michel" last="Mallaret">Michel Mallaret</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Grenoble, 38043 Grenoble, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Grenoble, 38043 Grenoble</wicri:regionArea><placeName><region type="region" nuts="2">Auvergne-Rhône-Alpes</region><region type="old region" nuts="2">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name sortKey="Peyriere, Helene" sort="Peyriere, Helene" uniqKey="Peyriere H" first="Helene" last="Peyrière">Helene Peyrière</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Montpellier, 34295 Montpellier, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Montpellier, 34295 Montpellier</wicri:regionArea><placeName><region type="region" nuts="2">Occitanie (région administrative)</region><region type="old region" nuts="2">Languedoc-Roussillon</region><settlement type="city">Montpellier</settlement></placeName></affiliation></author><author><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><affiliation wicri:level="3"><nlm:affiliation>CEIP-A Marseille, 13385 Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CEIP-A Marseille, 13385 Marseille</wicri:regionArea><placeName><region type="region" nuts="2">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author></analytic><series><title level="j">Therapie</title><idno type="eISSN">1958-5578</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Community Pharmacy Services (organization & administration)</term><term>Coronavirus Infections (epidemiology)</term><term>Drug Overdose (epidemiology)</term><term>France (epidemiology)</term><term>General Practitioners (organization & administration)</term><term>Health Personnel (organization & administration)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Quarantine (MeSH)</term><term>Substance-Related Disorders (complications)</term><term>Substance-Related Disorders (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>France (épidémiologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (épidémiologie)</term><term>Mauvais usage des médicaments prescrits (épidémiologie)</term><term>Médecins généralistes (organisation et administration)</term><term>Pandémies (MeSH)</term><term>Personnel de santé (organisation et administration)</term><term>Pneumopathie virale (épidémiologie)</term><term>Quarantaine (MeSH)</term><term>Services des pharmacies communautaires (organisation et administration)</term><term>Troubles liés à une substance (complications)</term><term>Troubles liés à une substance (épidémiologie)</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Drug Overdose</term><term>Pneumonia, Viral</term><term>Substance-Related Disorders</term></keywords><keywords scheme="MESH" qualifier="organisation et administration" xml:lang="fr"><term>Médecins généralistes</term><term>Personnel de santé</term><term>Services des pharmacies communautaires</term></keywords><keywords scheme="MESH" qualifier="organization & administration" xml:lang="en"><term>Community Pharmacy Services</term><term>General Practitioners</term><term>Health Personnel</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>France</term><term>Infections à coronavirus</term><term>Mauvais usage des médicaments prescrits</term><term>Pneumopathie virale</term><term>Troubles liés à une substance</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term><term>Quarantine</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term><term>Quarantaine</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role: among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (https://sfpt-fr.org/covid19). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32660776</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1958-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>4</Issue><PubDate><MedlineDate>2020 Jul - Aug</MedlineDate></PubDate></JournalIssue><Title>Therapie</Title><ISOAbbreviation>Therapie</ISOAbbreviation></Journal><ArticleTitle>Addictovigilance contribution during COVID-19 epidemic and lockdown in France.</ArticleTitle><Pagination><MedlinePgn>343-354</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0040-5957(20)30110-4</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.therap.2020.06.006</ELocationID><Abstract><AbstractText>Addictovigilance is a safety monitoring targeted at substances with potential for abuse and dependence. This vigilance was involved during the period of COVID-19 epidemic due to the significant changes in access to drugs and psychological disruption caused by the pandemic and lockdown. This article aims to present the different steps implemented by the French Addictovigilance network in collaboration with the French Health authorities from March to May 2020, including monitoring of potential harmful events, and scientific communication. The first events were identified through the continuity of the networking between the French addictovigilance centres and their partners: community pharmacies, general practitioners, specialized structures and emergency wards. As soon as the lockdown began, first cases of overdoses (lethal or not) were reported with opioids, mainly with methadone, and other opioids (heroin, oxycodone, tramadol or antitussive codeine). Lockdown-related noteworthy events consisted in clinical cases or other relevant information for which lockdown clearly played an important role: among the many substances identified at least once, pregabalin, benzodiazepines, cannabis, cocaine and nitrous oxide were the most significant in terms of prevalence, seriousness or particularly specific to the lockdown context. Despite significant decrease in the activity and travel limited to vital needs, community pharmacies continued to identify falsified prescriptions in this period, highlighting an increase in suspicious requests for pregabalin, codeine and tramadol. In parallel, the French addictovigilance network continued its communications efforts in the period, issuing a newsletter on tramadol, a press release on methadone and naloxone, and participating in the COVID-19 frequently asked questions (FAQs) of the French Society of Pharmacology and Therapeutic website (https://sfpt-fr.org/covid19). COVID-19 epidemic has been an important challenge for addictovigilance, and has proved that this monitoring is highly essential for alerting health professionals and health authorities to points of vigilance in the field of psychoactive substances.</AbstractText><CopyrightInformation>Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lapeyre-Mestre</LastName><ForeName>Maryse</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEIP-A Toulouse, 31000 Toulouse, France. Electronic address: maryse.lapeyre-mestre@univ-tlse3.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boucher</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEIP-A Lyon, 69424 Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daveluy</LastName><ForeName>Amélie</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEIP-A Bordeaux, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibaja</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>CEIP-A Nancy, 54035 Nancy, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouanjus</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>CEIP-A Toulouse, 31000 Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallaret</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEIP-A Grenoble, 38043 Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peyrière</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>CEIP-A Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Micallef</LastName><ForeName>Joëlle</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CEIP-A Marseille, 13385 Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>French Addictovigilance Network</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Therapie</MedlineTA><NlmUniqueID>0420544</NlmUniqueID><ISSNLinking>0040-5957</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003157" MajorTopicYN="N">Community Pharmacy Services</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062787" MajorTopicYN="N">Drug Overdose</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058005" MajorTopicYN="N">General Practitioners</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="N">Health Personnel</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization & administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011790" MajorTopicYN="Y">Quarantine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abuse</Keyword><Keyword MajorTopicYN="N">Addiction</Keyword><Keyword MajorTopicYN="N">Addictovigilance</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cocaine</Keyword><Keyword MajorTopicYN="N">Lockdown</Keyword><Keyword MajorTopicYN="N">Methadone</Keyword><Keyword MajorTopicYN="N">Nitrous oxide</Keyword><Keyword MajorTopicYN="N">Pregabalin</Keyword><Keyword MajorTopicYN="N">Psychoactive substances</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Bouquet</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>CEIP-A Poitiers, 86021 Poitiers, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Chaouachi</LastName><ForeName>Leila</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CEIP-A Paris, 75475 Paris, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Chevallier</LastName><ForeName>Cécile</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CEIP-A Lyon, 69424 Lyon, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Deheul</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>CEIP-A Lille, 59037 Lille, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Eiden</LastName><ForeName>Céline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CEIP-A Montpellier, 34295 Montpellier, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fouilhé</LastName><ForeName>Nathalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CEIP-A Grenoble, 38043 Grenoble, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fournier-Choma</LastName><ForeName>Chistine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CEIP-A Clermont-Ferrand, 63003 Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Frauger</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>CEIP-A Marseille, 13385 Marseille, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Guerlais</LastName><ForeName>Marylène</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CEIP-A Nantes, 44093 Nantes, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Le Boisselier</LastName><ForeName>Reynald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>CEIP-A Caen, 14033 Caen, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Miremont</LastName><ForeName>Ghada</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>CEIP-A Bordeaux, 33076 Bordeaux, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Roussin</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CEIP-A Toulouse, 31000 Toulouse, France.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Tournebize</LastName><ForeName>Juliana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CEIP-A Nancy, 54035 Nancy, France.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32660776</ArticleId><ArticleId IdType="pii">S0040-5957(20)30110-4</ArticleId><ArticleId IdType="doi">10.1016/j.therap.2020.06.006</ArticleId><ArticleId IdType="pmc">PMC7309935</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Auvergne-Rhône-Alpes</li><li>Grand Est</li><li>Languedoc-Roussillon</li><li>Lorraine (région)</li><li>Midi-Pyrénées</li><li>Nouvelle-Aquitaine</li><li>Occitanie (région administrative)</li><li>Provence-Alpes-Côte d'Azur</li><li>Rhône-Alpes</li></region><settlement><li>Bordeaux</li><li>Grenoble</li><li>Lyon</li><li>Marseille</li><li>Montpellier</li><li>Nancy</li><li>Toulouse</li></settlement></list><tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Lapeyre Mestre, Maryse" sort="Lapeyre Mestre, Maryse" uniqKey="Lapeyre Mestre M" first="Maryse" last="Lapeyre-Mestre">Maryse Lapeyre-Mestre</name></region><name sortKey="Boucher, Alexandra" sort="Boucher, Alexandra" uniqKey="Boucher A" first="Alexandra" last="Boucher">Alexandra Boucher</name><name sortKey="Daveluy, Amelie" sort="Daveluy, Amelie" uniqKey="Daveluy A" first="Amélie" last="Daveluy">Amélie Daveluy</name><name sortKey="Gibaja, Valerie" sort="Gibaja, Valerie" uniqKey="Gibaja V" first="Valérie" last="Gibaja">Valérie Gibaja</name><name sortKey="Jouanjus, Emilie" sort="Jouanjus, Emilie" uniqKey="Jouanjus E" first="Emilie" last="Jouanjus">Emilie Jouanjus</name><name sortKey="Mallaret, Michel" sort="Mallaret, Michel" uniqKey="Mallaret M" first="Michel" last="Mallaret">Michel Mallaret</name><name sortKey="Micallef, Joelle" sort="Micallef, Joelle" uniqKey="Micallef J" first="Joëlle" last="Micallef">Joëlle Micallef</name><name sortKey="Peyriere, Helene" sort="Peyriere, Helene" uniqKey="Peyriere H" first="Helene" last="Peyrière">Helene Peyrière</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000064 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000064 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32660776
|texte= Addictovigilance contribution during COVID-19 epidemic and lockdown in France.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32660776" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidFranceV1
| This area was generated with Dilib version V0.6.37. |  |